Literature DB >> 18672260

Primary HIV-1 R5 isolates from end-stage disease display enhanced viral fitness in parallel with increased gp120 net charge.

Johanna Repits1, Jasminka Sterjovski, Daniel Badia-Martinez, Mattias Mild, Lachlan Gray, Melissa J Churchill, Damian F J Purcell, Anders Karlsson, Jan Albert, Eva Maria Fenyö, Adnane Achour, Paul R Gorry, Marianne Jansson.   

Abstract

To better understand the evolution of the viral envelope glycoproteins (Env) in HIV-1 infected individuals who progress to AIDS maintaining an exclusive CCR5-using (R5) virus population, we cloned and sequenced the env gene of longitudinally obtained primary isolates. A shift in the electrostatic potential towards an increased net positive charge was revealed in gp120 of end-stage viruses. Residues with increased positive charge were primarily localized in the gp120 variable regions, with the exception of the V3 loop. Molecular modeling indicated that the modifications clustered on the gp120 surface. Furthermore, correlations between increased Env net charge and lowered CD4(+) T cell counts, enhanced viral fitness, reduced sensitivity to entry inhibitors and augmented cell attachment were disclosed. In summary, this study suggests that R5 HIV-1 variants with increased gp120 net charge emerge in an opportunistic manner during severe immunodeficiency. Thus, we here propose a new mechanism by which HIV-1 may gain fitness.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18672260     DOI: 10.1016/j.virol.2008.06.014

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  27 in total

1.  Impact of CCR5delta32 host genetic background and disease progression on HIV-1 intrahost evolutionary processes: efficient hypothesis testing through hierarchical phylogenetic models.

Authors:  Diana Edo-Matas; Philippe Lemey; Jennifer A Tom; Cèlia Serna-Bolea; Agnes E van den Blink; Angélique B van 't Wout; Hanneke Schuitemaker; Marc A Suchard
Journal:  Mol Biol Evol       Date:  2010-12-06       Impact factor: 16.240

2.  Impact of mutations outside the V3 region on coreceptor tropism phenotypically assessed in patients infected with HIV-1 subtype B.

Authors:  Laura Monno; Annalisa Saracino; Luigia Scudeller; Grazia Punzi; Gaetano Brindicci; Maurantonio Altamura; Antonella Lagioia; Nicoletta Ladisa; Gioacchino Angarano
Journal:  Antimicrob Agents Chemother       Date:  2011-08-29       Impact factor: 5.191

3.  Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5.

Authors:  Zahra F Parker; Shilpa S Iyer; Craig B Wilen; Nicholas F Parrish; Kelechi C Chikere; Fang-Hua Lee; Chuka A Didigu; Reem Berro; Per Johan Klasse; Benhur Lee; John P Moore; George M Shaw; Beatrice H Hahn; Robert W Doms
Journal:  J Virol       Date:  2012-12-26       Impact factor: 5.103

4.  Viral envelope is a major determinant of enhanced fitness of a multidrug-resistant HIV-1 variant.

Authors:  Hiroshi Mohri; Nicole Prada; Martin Markowitz
Journal:  J Acquir Immune Defic Syndr       Date:  2015-04-15       Impact factor: 3.731

5.  An altered and more efficient mechanism of CCR5 engagement contributes to macrophage tropism of CCR5-using HIV-1 envelopes.

Authors:  Jasminka Sterjovski; Michael Roche; Melissa J Churchill; Anne Ellett; William Farrugia; Lachlan R Gray; Daniel Cowley; Pantelis Poumbourios; Benhur Lee; Steven L Wesselingh; Anthony L Cunningham; Paul A Ramsland; Paul R Gorry
Journal:  Virology       Date:  2010-06-08       Impact factor: 3.616

6.  Evolution of human immunodeficiency virus type 1 in a patient with cross-reactive neutralizing activity in serum.

Authors:  Marit J van Gils; Diana Edo-Matas; Emma J Bowles; Judith A Burger; Guillaume B Stewart-Jones; Hanneke Schuitemaker
Journal:  J Virol       Date:  2011-06-08       Impact factor: 5.103

7.  Mode of coreceptor use by R5 HIV type 1 correlates with disease stage: a study of paired plasma and cerebrospinal fluid isolates.

Authors:  Ulf Karlsson; Liselotte Antonsson; Johanna Repits; Patrik Medstrand; Christer Owman; Karin Kidd-Ljunggren; Lars Hagberg; Bo Svennerholm; Marianne Jansson; Magnus Gisslén; Bengt Ljungberg
Journal:  AIDS Res Hum Retroviruses       Date:  2009-12       Impact factor: 2.205

8.  Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design.

Authors:  Li-Hua Ping; Sarah B Joseph; Jeffrey A Anderson; Melissa-Rose Abrahams; Jesus F Salazar-Gonzalez; Laura P Kincer; Florette K Treurnicht; Leslie Arney; Suany Ojeda; Ming Zhang; Jessica Keys; E Lake Potter; Haitao Chu; Penny Moore; Maria G Salazar; Shilpa Iyer; Cassandra Jabara; Jennifer Kirchherr; Clement Mapanje; Nobubelo Ngandu; Cathal Seoighe; Irving Hoffman; Feng Gao; Yuyang Tang; Celia Labranche; Benhur Lee; Andrew Saville; Marion Vermeulen; Susan Fiscus; Lynn Morris; Salim Abdool Karim; Barton F Haynes; George M Shaw; Bette T Korber; Beatrice H Hahn; Myron S Cohen; David Montefiori; Carolyn Williamson; Ronald Swanstrom
Journal:  J Virol       Date:  2013-04-24       Impact factor: 5.103

9.  A combinatorial approach for targeted delivery using small molecules and reversible masking to bypass nonspecific uptake in vivo.

Authors:  Q Shi; A T Nguyen; Y Angell; D Deng; C-R Na; K Burgess; D D Roberts; F C Brunicardi; N S Templeton
Journal:  Gene Ther       Date:  2010-05-13       Impact factor: 5.250

10.  Movements of HIV-virions in human cervical mucus.

Authors:  Hacène Boukari; Beda Brichacek; Pamela Stratton; Sheila F Mahoney; Jeffrey D Lifson; Leonid Margolis; Ralph Nossal
Journal:  Biomacromolecules       Date:  2009-09-14       Impact factor: 6.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.